Drug Development
Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in achondroplasia, Truist Securities analysts said Thursday.
FEATURED STORIES
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Researchers from UCLA believe they may have a possible new approach to treating, and potentially eradicating HIV.
Emergent BioSolutions, Vir Biotechnology and Thermo Fisher, come into 2022 with reports of new opportunities, new vaccines, and partnership expansions.
Affini-T Therapeutics unveiled its mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
Researchers from the Medical University of Bialystok in Poland identified a gene that appears to double the risk of severe COVID-19.
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
Vaccine development is experiencing a resurgence in the wake of the COVID-19 pandemic, with companies developing a variety of approaches.
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of its BBP-398 with Amgen’s Lumakras in advanced solid tumors with the KRAS G12C mutation.
Denali Therapeutics announced that the FDA had placed a clinical hold on the IND application for DNL919 and would receive an official clinical hold letter from the agency in about 30 days.